Allergy Therapeutics (AGY): Hong Kong dual listing
This situation live
AGY Allergy Therapeutics
12 Dec 2025 · Announced 6 Nov 2025; expected first half 2026 · +13% until the next step
The Potential Equity Raise would be carried out ahead of the potential dual listing of the Company's shares on the Hong Kong Stock Exchange, which was announced on 6 November 2025 and which is expecte
19 Jan 2026 · Still exploring potential dual primary listing · −11% until the next step
while it continues to explore a potential dual primary listing on the Hong Kong Stock Exchange
31 Mar 2026 · Still exploring dual primary listing · −23% until the next step
- Company continues to explore potential dual primary listing on Hong Kong Stock Exchange
15 Jun 2026 · Still exploring; CFO awarded LTIP for workload · −32% until the next step
in recognition of the significantly higher level of corporate activity as the Company continues to explore the potential dual primary listing of its ordinary shares on the Main Board of The Stock Exch
28 Jul 2026 · Still exploring; Executive Chairman appointed to lead · +10% until the next step
particularly as the Group continues to explore a potential dual primary listing on The Stock Exchange of Hong Kong Limited, alongside its existing listing on AIM.
29 Jul 2026 · Still exploring; no timetable · −24% since
The Group continues to explore a potential dual primary listing on The Hong Kong Stock Exchange.
Hong Kong dual listing
Still exploring; no timetable
Every step · 6
- 12 Dec 2025 Announced 6 Nov 2025; expected first half 2026 – The Potential Equity Raise would be carried out ahead of the potential dual listing of the Company's shares on the Hong Kong Stock Exchange, which was... ↗
- 19 Jan 2026 Still exploring potential dual primary listing – while it continues to explore a potential dual primary listing on the Hong Kong Stock Exchange ↗
- 31 Mar 2026 Still exploring dual primary listing – - Company continues to explore potential dual primary listing on Hong Kong Stock Exchange ↗
- 15 Jun 2026 Still exploring; CFO awarded LTIP for workload – in recognition of the significantly higher level of corporate activity as the Company continues to explore the potential dual primary listing of its... ↗
- 28 Jul 2026 Still exploring; Executive Chairman appointed to lead – particularly as the Group continues to explore a potential dual primary listing on The Stock Exchange of Hong Kong Limited, alongside its existing listing on AIM. ↗
- 29 Jul 2026 Still exploring; no timetable – The Group continues to explore a potential dual primary listing on The Hong Kong Stock Exchange. ↗
What is happening
Allergy Therapeutics: Hong Kong dual listing – Still exploring; no timetable. ['Still exploring; no timetable']
- In short
- The company began exploring a dual primary listing on HKEX in December 2025. Helge Weiner-Trapness was appointed Executive Chairman on 28 July 2026 to lead it. The 29 July 2026 update says the Group continues to explore it, with no timetable or decision.
- Announced
- 12 Dec 2025 · Announced 6 Nov 2025; expected first half 2026
- Latest
- 29 Jul 2026 · Still exploring; no timetable
- Status
- Continuing to explore dual primary listing on HKEX
- Award reason
- CFO LTIP award recognises significantly higher level of corporate activity
- Timetable
- None stated
- Leadership
- Helge Weiner-Trapness appointed Executive Chairman on 28 July 2026
- Stated benefits
- Access to key new markets, expansion into Asia, platform to develop R&D capabilities
Briefing Pro
New to Allergy Therapeutics? Get up to speed in 2 minutes.
What it does, how it got here, what management promised and delivered – written from its own announcements.
Get the AGY briefing →From the company's own announcements. Not investment advice.
Also at Allergy Therapeutics 2 open
Project milestonesVLP Peanut PROTECT trial – Still exploring; no timetable
Dilutive fundraisePotential equity raise – No raise; debt funded, cash £24.2m
Allergy Therapeutics – company page →